Compare VanEck Rare Earth/Strategic Metals (REMX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Vertex Pharmaceuticals Incorporated — how do they compare? VanEck Rare Earth/Strategic Metals trades at $75.47, while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| REMX | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $557.96 |
52-Week Low | $57.35 | $376.62 |
Market Cap | — | $134.06B |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX trades at $76.72, up 1.4% today, but technical indicators show a bearish trend with moving averages signaling caution. The ETF faces high volatility (~50% annualized) and significant portfolio turnover, making it unsuitable for conservative investors. Recent news highlights institutional interest with Bank of America increasing its stake by 72.1% in the latest quarter (Defense World, August 14, 2026).
The outlook for REMX is mixed—geopolitical tensions and U.S. efforts to secure rare earth supply chains offer long-term potential, but high volatility and China-dependent holdings pose risks. Investors should weigh strategic exposure against the ETF's aggressive risk profile and monitor tariff policies impacting the sector.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
